scorecard

You Searched For "Emcure Pharma IPO gmp" and got 20 results


Sort By:


Business Insider Latest Story Image
2 mins read

Emcure Pharma IPO allotment – How to check allotment, IPO GMP, listing date and more

Pune-based Emcure Pharma, a pharmaceutical company that develops, manufactures and markets a wide r…

Business Insider Latest Story Image
1 min read

Emcure Pharma shares zoom over 31% in debut trade

Later, the company's stock zoomed 37.30 per cent to Rs 1,384 on BSE and 37.40 per cent to Rs 1,…

PTI   


Business Insider Latest Story Image
4 mins read

Emcure Pharma opens for subscription today: Should you subscribe? Know all about it here

Retail investors can buy a minimum of 1 lot (14 shares) at ​Rs 14,112, or 14 lots (196 shares) at R…

Business Insider Latest Story Image
2 mins read

Bain Capital-backed Emcure Pharma to float ₹1,952-crore IPO on July 3

The IPO comprises fresh issuance of equity shares worth Rs 800 crore and an Offer For Sale (OFS…

PTI   


Business Insider Latest Story Image
2 mins read

Concord Biotech lists at 21% premium, beats grey market expectations

Ahmedabad-based pharma company Concord Biotech made its D-street debut at a 21% premium on Friday, …

Business Insider Latest Story Image
3 mins read

Blue Jet Healthcare closes debut session with 14.4% listing gains

The stock of pharma intermediates manufacturer Blue Jet Healthcare debuted at 4% premium on the bou…

Business Insider Latest Story Image
2 mins read

Mankind Pharma IPO: Here’s how to check allotment status online

Condom manufacturer Mankind Pharma is likely to announce the allotment status of its initial public…

Business Insider Latest Story Image
6 mins read

Mankind Pharma stock runs up in trade after listing at 20% premium

After listing at a 20% premium, condom manufacturer Mankind Pharma’s stock ran up 9.5% on Tuesday. …

Business Insider Latest Story Image
4 mins read

Condom maker Mankind Pharma’s ₹4,326 crore IPO to open next week on April 25

The IPO will comprise an offer for sale (OFS) of over 4 crore equity shares by the promoters a…

Business Insider Latest Story Image
2 mins read

Emcure Pharmaceuticals to raise ₹1,100 crore via fresh issue; Bain Capital to sell stake via IPO

Pune-based Emcure Pharmaceuticals has come forth again to publicly list its shares on exchanges. …

Business Insider Latest Story Image
2 mins read

Innova Captab closes maiden trading session with 21% listing gains

Pharma company Innova Captab made a tepid market debut on Friday, at a 1.8% premium. The stock list…

Business Insider Latest Story Image
5 mins read

Analysts suggest subscribing to this pharma company IPO on discounted valuation and strong product portfolio than peers

Amid myriad initial public offerings (IPO) going on, here is another one worth giving attention to,…

Business Insider Latest Story Image
2 mins read

Gland Pharma’s grey market premium rises ahead of listing today

The shares of the recently concluded Gland Pharma IPO are soaring in the grey market ahead of its l…

Business Insider Latest Story Image
4 mins read

LIC IPO: Price band, important dates, GMP and all you need to know

LIC IPO is all set to open its IPO next week and is expected to raise around ₹21,000 crore. The go…

Business Insider Latest Story Image
3 mins read

Gland Pharma ₹1,250 crore IPO to open next week — sets price band at ₹1,490-1,500

The IPO of Hyderabad-based Gland Pharma, which is promoted by China’s Fosun Pharma, will open next …

Business Insider Latest Story Image
5 mins read

IPOs pick up steam in last three months of 2022 – Strong pipeline likely to propel listings in 2023

The primary markets have turned optimistic since September, compensating for a lull in initial publ…

Business Insider Latest Story Image
3 mins read

Too early to say primary market is seeing a revival

Too early to say primary market is seeing a revival

Business Insider Latest Story Image
5 mins read

The IPO excitement may be softer in 2022 but that can be a good thing for investors

That kind of unbridled enthusiasm is unlikely in 2022, according to Ajay Saraf, head of investme…